A Phase I Trial of WRSS1, a Shigella sonnei Live Oral Vaccine in Bangladeshi Adults and Children
This article, published in Human Vaccines & Immunotherapeutics, reports the results of a study to evaluate the safety, tolerability, and immunogenicity of a Shigella sonnei vaccine candidate. Results indicate that the vaccine candidate is safe and produced an immune response in Bangladeshi adults and children. The data also suggest that live, oral Shigella vaccine candidates, including WRSS1, can potentially be evaluated in children under 2 years of age, who comprise the target population in an endemic environment. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author: Raqib R, Sarker P, Zaman K, et al.
» Visit web page (English)
(Located at www.tandfonline.com)
Citation: Raqib R, Sarker P, Zaman K, et al. A Phase I Trial of WRSS1, a Shigella sonnei Live Oral Vaccine in Bangladeshi Adults and Children. Human Vaccines & Immunotherapeutics. 2019;15(6):1326-1337.
Resource types: Peer-reviewed journal
Diseases/vaccines: Shigellosis and enterotoxigenic Escherichia coli (ETEC)